1. Academic Validation
  2. Chronic NG-nitro-l-arginine methyl ester (L-NAME) administration in C57BL/6J mice induces a sustained decrease in c-kit positive cells during development of cardiac hypertrophy

Chronic NG-nitro-l-arginine methyl ester (L-NAME) administration in C57BL/6J mice induces a sustained decrease in c-kit positive cells during development of cardiac hypertrophy

  • J Physiol Pharmacol. 2013 Dec;64(6):727-36.
R J Ocsan 1 Y N Lai K V Prabhu B D Hambly C S McLachlan
Affiliations

Affiliation

  • 1 Discipline of Pathology, Sydney Medical School, University of Sydney, Sydney, Australia. reperfusion@hotmail.com.
PMID: 24388887
Abstract

Chronic NG-nitro-l-arginine methyl ester (L-NAME) administration induces cardiac hypertrophy in rodent models. Our aims is to determine the role of c-Kit expression in L-NAME induced cardiac hypertrophy. 12-20 week old C57BL/6J mice (5 per group) were administered L-NAME (0.325mg/ml) in the drinking water. Hearts were excised at 1-day, 2-days, 5-days, 2-weeks or 6-weeks; or controls which received no L-NAME. Ventricular cross-sectional wall thickness and individual cardiac myocytes cross-sectional area and cardiomyocyte/nuclear ratio to determine cardiac hypertrophy. Immuno-histochemical staining for c-Kit, sca-1 and BCRP undertaken. Six weeks L-NAME administration induced significant cardiac hypertrophy compared to control hearts, evidenced by an increase in the thickness of the cross-sectional free ventricular wall (p<0.05) and an increase in mean individual cross-sectional area of cardiac myocytes in the LV wall (p<0.007). We observed c-Kit(+) cells (predominately non-mast cell sub-types) in both healthy mice and in the L-NAME treated mice. c-Kit staining in the left ventricular cross sections following L-NAME remained stable at 1 and 2 days compared to controls (p=NS). After 5 days of L-NAME we observed c-Kit expression to decrease below control levels (p<0.05) and these lower levels were sustained at 2 and 6 weeks. c-Kit expression does not decrease during two days of L-NAME administration, suggesting, firstly, that the later decrease in c-Kit is not due to NOS inhibition directly and, secondly, there is the possibility for c-Kit(+) cell differentiation into other cell types, possibly inducing myocardial cellular hyperplasia, without significant replacement of the original pool of c-Kit(+) cells.

Figures
Products